{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"source": "/home/guanzhideng145/research/ip_portal/patent_kg/patents/821.pdf"}, "page_content": "<210> SEQ ID NO 9 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRNA\n\n<400> SEQUENCE: 9\n\nttectattgt aactgaaggg atagttggct\n\n<210> SEQ ID NO 10 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRAN\n\n<400> SEQUENCE: 10\n\nccaaatatge gtactaactt gtagcaacca\n\n<210> SEQ ID NO 11 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRNA\n\n<400> SEQUENCE: 11\n\nagttgegggg ccccagtcct ttacagaagt\n\n<210> SEQ ID No 12 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRNA\n\n<400> SEQUENCE: 12\n\nttetgegttg ctaaaatgge getgegctta\n\n10\n\n-cont inued\n\n30\n\n30\n\n30\n\n30\n\n30\n\n30\n\n30\n\nNov. 4, 2021\n\nUS 2021/0340592 Al\n\nNov. 4, 2021\n\n-cont inued\n\n<210> SEQ ID NO 13 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRNA <400> SEQUENCE: 13 aatcttagaa acgtgaaaac ccactcttgg <210> SEQ ID NO 14 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: gRNA <400> SEQUENCE: 14 ttgetttttt gttcgagaaa teggagcage\n\n30\n\n30\n\n1. A fusion protein formed by BASU and dCasRx.\n\n2. The fusion protein according to claim 1, which is BASU-dCasRx or dCasRx-BASU.\n\ncalculating the false discovery rate of enrichment by using Rank product; more preferably, the critical value is set as enrichment22 folds and FDR<0.05;\n\n3. An expression vector for expressing the fusion protein according to claim 1.\n\n4. Acomposition comprising: the fusion protein according claim 1 and/or the expression vector according to claim a gRNA targeting the target IncRNA;\n\nto\n\nand\n\npreferably, the target IncRNA is XIST, DANCR, or MALAT1.\n\n3,\n\npreferably, the method further comprises:\n\napplying the obtained proteins for genetic ontological analysis or protein interaction network analysis; and/or", "type": "Document"}}